Susquehanna International Group, LLP Verve Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $59,840 - $106,896	13,600 New	13,600 $65,000
Q1 2024 May 07, 2024	SELL	$10.81 - $17.96 $339,434 - $563,944	-31,400 Reduced 27.05%	84,700 $1.12 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $103,428 - $218,790	11,700 Added 11.21%	116,100 $1.62 Million
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $1.04 Million - $1.89 Million	90,700 Added 662.04%	104,400 $1.38 Million
Q2 2023 Aug 11, 2023	SELL	$13.34 - $19.9 $349,508 - $521,379	-26,200 Reduced 65.66%	13,700 $256,000
Q1 2023 May 16, 2023	SELL	$14.3 - $24.01 $2.2 Million - $3.69 Million	-153,500 Reduced 79.37%	39,900 $575,000
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $851,445 - $1.94 Million	47,700 Added 32.74%	193,400 $3.74 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $534,546 - $1.42 Million	34,200 Added 30.67%	145,700 $5.01 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $1.24 Million - $2.58 Million	111,500 New	111,500 $1.7 Million

184

73.4M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $474M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.